Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia by Hollink, I.H.I.M. (Iris) et al.
Original Articles
Funding: this work was funded
by the KOCR foundation (IHIMH
and BVB) and the Netherlands
Organisation for Scientific
Research (NWO) (BVB). This
work was further supported in
part by the Deutsche Krebshilfe
(DR). and the Czech Ministry of
Education (MSM0021620813)
(JT). 
Acknowledgments: we would like
to thank Jules Meijerink
(Erasmus MC–Sophia Children’s
Hospital) for his help with the
NOTCH1 mutation screening. 
Manuscript received on July 28,
2010. Revised version arrived
on October 27, 2010.
Manuscript accepted on
November 23, 2010.
Correspondence: 
C. Michel Zwaan, MD, PhD,
Erasmus MC - Sophia Children’s
Hospital, Dept. of Pediatric
Oncology/Hematology, Dr.
Molewaterplein 60 3015 GJ
Rotterdam, the Netherlands.
Phone: international
+310.107036691. 
Fax: international
+31.0107036801. 
E-mail: c.m.zwaan@eras-
musmc.nl
The online version of this article
has a Supplementary Appendx.
Background
Dysfunctioning of CCAAT/enhancer binding protein α (C/EBPα) in acute myeloid leukemia
can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter
hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable out-
come, but this may be restricted to the case of double mutations in CEBPA in adult acute
myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations
are limited to one series, and data on promoter hypermethylation are lacking. Our objective
was to investigate the characteristics, gene expression profiles and prognostic impact of the dif-
ferent CEBPA aberrations in pediatric acute myeloid leukemia.
Design and Methods
We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct
sequencing, and for promoter hypermethylation by methylation-specific polymerase chain
reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus
2.0 arrays) of this cohort (n=237).
Results
Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-
mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-
year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04),
and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor
cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an inde-
pendent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination
of screening for promoter hypermethylation and gene expression profiling identified five
patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically
expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles
showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common
hallmark of abrogated C/EBPα-functioning in these acute myeloid leukemias.
Conclusions
We showed the independent favorable outcome of patients with CEBPA double-mutant acute
myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve
risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced
cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating
that further investigation of this aberration is needed. Furthermore, clustering of gene expres-
sion profiles provided insight into the biological similarities and diversities of the different aber-
rations in CEBPA in pediatric acute myeloid leukemia.
Key words: Pediatric acute myeloid leukemia, CEBPA mutation, promoter hypermethylation,
molecular marker, prognostic significance. 
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Introduction 
Current risk-group classification in pediatric acute
myeloid leukemia (AML) is determined by recurrent cyto-
genetic aberrations together with early treatment
response.1 However, the majority of patients are stratified
in the intermediate risk group, including patients with
cytogenetically normal AML, representing 20-25% of all
children with AML. Molecular markers with prognostic
implications have been identified in pediatric AML, such
as internal tandem duplications of the FTL3 gene
(FLT3/ITD), and mutations in NPM1 and the Wilms tumor
1 (WT1) gene, which may further refine risk-group classi-
fication.2-4
Mutations in CEBPA, encoding the CCAAT/enhancer
binding protein alpha (C/EBPα), have also been detected
in AML.5,6 C/EBPα is one of the crucial transcription fac-
tors for myeloid cell development. Targeted disruption of
the CEBPA gene results in a selective early block of granu-
locyte differentiation.7,8 C/EBPα function is frequently
abrogated in AML by mutations, but also by (post)-tran-
scriptional or post-translational inhibition due to dysregu-
lation by oncogenes such as AML1-ETO, CBF-MYH11
and FLT3/ITD.9-13 More recently, epigenetic modification
through hypermethylation of the CEBPA promoter, result-
ing in CEBPA silencing, has also been reported.14,15
Various mutations throughout CEBPA have been
described, but two locations are most frequently affect-
ed.16-18 N-terminal frame shift mutations are located
between the major translational start site and a second
ATG further downstream. They result in truncation of the
full-length p42 isoform of C/EBPα, while preserving the
shorter p30 isoform, which has been shown to inhibit the
function of full-length p42.9 C-terminal mutations are in-
frame insertions or deletions located in the basic leucine
zipper (bZIP) domain, and impair DNA binding and/or
homo-and heterodimerization.19 The majority of AML
patients with CEBPAmutations harbor a mutation at both
locations (CEBPA double mutants), and these are typically
on different alleles, resulting in the lack of wild-type
C/EBPα p42 expression in these cases.20,21 However, single
CEBPA mutations also occur, in which expression of the
wild-type product is retained, albeit at lower levels. 
CEBPA mutations are found in 5% to 14% of adult
patients with AML, and are associated with a favorable
outcome in such patients.5,6,21-24 In contrast, CEBPA pro-
moter hypermethylation has been suggested to confer a
poor outcome.15 Pediatric data are available from two
studies, showing CEBPA mutations in 4.5% and 6% of
cases, and only the Children’s Oncology Group reported
outcome data according to CEBPA status, which con-
firmed the association with a favorable outcome.25,26
Recently, two adult studies showed that the favorable
prognosis was associated uniquely with CEBPA double-
mutant AML, but not with the presence of a single CEBPA
mutation.27,28 In the Children’s Oncology Group study,
however, pediatric patients with CEBPA single-mutant
AML showed a favorable outcome comparable to that of
children with double-mutant AML. Pediatric data on
CEBPA promoter hypermethylation are lacking to date.
Interestingly, adult studies showed a highly characteris-
tic gene expression signature for CEBPA double-mutant
AML, in contrast to that for single-mutant AML.27 It is also
interesting that CEBPA promoter hypermethylated cases
showed a similar signature to that for the CEBPA double-
mutants, which is apparently characterized by the lack of
C/EBPα functioning.15
In this study we investigated the characteristics, expres-
sion profiles and impact of CEBPAmutations and promot-
er hypermethylation in a large series of children with
AML.
Design and Methods
Study cohort 
Viable frozen bone marrow or peripheral blood samples taken
at initial diagnosis from 252 children with AML were provided
based on availability by the Dutch Childhood Oncology Group
(DCOG; The Hague, the Netherlands), the AML-‘Berlin-Frankfurt-
Münster’ Study Group (AML-BFM-SG; Hannover, Germany, and
Prague, Czech Republic) and the Hôpital Saint-Louis (Paris,
France). In addition, 33 paired initial diagnosis-relapse bone mar-
row or peripheral blood samples, and seven paired initial diagno-
sis-remission bone marrow samples were provided by the DCOG
and AML-BFM-SG. Institutional review board approval for these
studies was obtained according to local laws and regulations. Each
study group performed a central review of the morphological,
immunophenotypic and cytogenetic classifications, and provided
data on the clinical follow-up.  
After thawing, leukemic cells were isolated from these samples
as previously described.29 The percentages of blasts were greater
than 80%, as assessed morphologically on May-Grünwald-
Giemsa-stained cytospin slides. Genomic DNA and total cellular
RNA were extracted using TRIzol reagent (Invitrogen, Breda, the
Netherlands), as described before.30
Survival analysis was restricted to the patients with de novo
AML who were treated according to DCOG and AML-BFM-SG
studies (i.e. DCOG/AML-BFM 87, DCOG 92/94, DCOG 97,
AML-BFM 98 and 04) to reduce treatment variability; these
patients accounted for the majority of subjects in our study
(n=185). Patients treated according to other protocols (n=43), and,
in addition, patients with PML-RARα (n=15) or with secondary
AML (n=8) were excluded. Details of the treatment protocols and
overall outcome data have already been published, with the
exception of those for the AML-BFM 04 study, which was closed
recently. In these protocols, treatment consisted of four or five
blocks of intensive chemotherapy, using a standard cytarabine and
anthracycline backbone. Stem cell transplantation in first complete
remission was used only in selected high-risk patients. There was
no statistically significant difference between the treatment proto-
cols for obtaining complete remission (P=0.65) or event-free sur-
vival (P=0.41), but for overall survival there was a difference
between the protocols (P=0.04). However, patients with CEBPA
single-mutated AML, double-mutated AML and wild-type AML
were equally distributed over the different treatment protocols
(P=0.28).
Cytogenetic and molecular analysis
Samples were routinely screened for cytogenetic aberrations
using standard chromosome-banding karyotyping, and further
analyzed for recurrent non-random genetic aberrations charac-
teristic of AML, including t(15;17), inv(16), t(8;21) and MLL gene
rearrangements, using reverse transcriptase polymerase chain
reaction (RT-PCR) and/or fluorescent in situ hybridization (FISH),
by each study group. In cases of lacking data, RT-PCR or FISH
was performed at the laboratory of Pediatric Oncology of the
Erasmus MC-Sophia Children’s Hospital. 
Hotspot regions for mutations of c-KIT, FLT3, MLL, NPM1,
PTPN11, N-RAS, K-RAS and WT1 were screened for, as previ-
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ously described.2 Regions of NOTCH1 known to be mutated in
T-cell acute lymphoblastic leukemia [heterodimerization
domain (HD), exons 26 and 27; proline-glutamate-serine-
threonine-rich domain (PEST), exon 34] were also analyzed for
the presence of mutations with a (nested) PCR-based direct
sequencing approach.31
Analysis of CEBPA mutations and promoter 
hypermethylation
Mutation analysis of CEBPA was performed as previously
described,21 with minor modifications. Primer sequences and PCR
conditions are described in Online Supplementary Table S1.
Genomic DNA was amplified using specific PCR primers, i.e.
primers 1 and 10, and 4 and 8, to cover the whole CEBPA gene.
Purified PCR products were directly sequenced from both strands
using the described primers on an ABI Prism 3100 genetic analyzer
(Applied Biosystems, Foster City, CA, USA). The sequence data
were analyzed using CLC Workbench version 3.5.1 (CLC Bio,
Aarhus, Denmark). 
For methylation analysis of the promoter region of CEBPA,
genomic DNA was treated with sodium bisulfite using the EZ
DNA Methylation kit (Zymo Research, Orange, CA USA) accord-
ing to the manufacturer’s protocol. The bisulfite-treated DNA was
used as a template for methylation-specific PCR and unmethyla-
tion-specific PCR, which were performed as previously
described.14 Both methylation-specific and unmethylation-specific
PCR products were subsequently separated by gel electrophoresis
and visualized with ethidium bromide.
Gene expression profiling and analysis
The integrity of total RNA was checked using the Agilent 2100
Bio-analyzer (Agilent, Santa Clara, CA, USA). Biotinylated cRNA
was synthesized, hybridized and processed on the Affymetrix
Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara,
CA, USA) according to the manufacturer’s guidelines.
Unsupervised clustering analysis was performed and visualized as
previously described.32 Briefly, probe set intensity values were nor-
malized using MAS5.0 software and values less than 30 were set
at 30. For each probe set the geometric mean of the intensity val-
ues of all samples was calculated. The level of expression of each
probe set in every sample was then determined relative to this
geometric mean and logarithmically transformed (on a base 2
scale). The transformed expression data were subsequently
imported into OmniViz software, (OmniViz v3.7, Tewksbury, MA
USA). Pairwise correlations between the gene expression profiles
of the 237 samples were calculated with Pearson’s correlation on
the basis of 1608 differently expressed probe sets representing the
subset of probe sets with a 16-factor increase or decrease relative
to the geometric mean. 
To test the probe set prediction signatures previously described
in adult AML for our pediatric CEBPA silenced cases and CEBPA
single- and double-mutant cases, normalized probe set intensities
for the 237 cases were used in a linear prediction algorithm (linear
discriminant analysis; equal prior probabilities, predicting four
variables: Partek v6.09.1008, Missouri, USA), with both the
described 21- and 9-probe sets.15,27 Prediction results of samples
were visualized using a principal component analysis scatterplot
(Partek), and both cases and probe sets were hierarchically clus-
tered using Euclidean distance (Genemaths XT, Applied Maths,
Austin, TX, USA).
Other statistical analyses
Statistical analyses were performed with SPSS 15.0 (SPSS Inc.
Chicago, IL, USA). Variables were compared using the χ2 or
Fisher’s exact test for categorical values, the Mann-Whitney-U test
for continuous values, and the Kruskal-Wallis test when more than
two groups were compared.
To assess outcome, the following parameters were used: com-
plete remission (defined as less than 5% blasts in the bone mar-
row, with regeneration of trilineage hematopoiesis plus absence of
leukemic cells in the cerebrospinal fluid or elsewhere), probability
of event-free survival (defined as the time between diagnosis and
first event, including failure to achieve remission, relapse, death
from any cause or second malignancy) and the probability of over-
all survival (defined as the time between diagnosis and death). The
probabilities of event-free and overall survival were estimated by
the Kaplan-Meier method, and compared using the log-rank test.
The independency of prognostic factors was examined by multi-
variate Cox regression analysis. All tests were two-tailed and P
values less than 0.05 were considered statistically significant.
Results
Single and double CEBPA mutations in pediatric acute
myeloid leukemia
We identified 34 CEBPA mutations in 20 out of 252
(7.9%) diagnostic samples from patients by sequencing
the entire coding region (Figure 1A, Online Supplementary
Table S2). Of these, 13 cases had the combination of an N-
terminal frame shift mutation and an in-frame mutation in
the bZIP region. One case combined an N-terminal frame
shift mutation with a frame shift-causing insertion before
the bZIP region. These 14 cases (70%) are henceforth
referred to as CEBPA double mutants. The other six cases
carried a single CEBPA mutation: four had in-frame bZIP
mutations and two had frame shift mutations in the TAD2
domain and before the bZIP domain, respectively. The lat-
ter two cases do not represent the classical N-terminal
mutation, as the C/EBPα p30 isoform is also affected, but
because of their functional consequence they were classi-
fied as mutations. 
Cases with an in-frame insertion polymorphism in
I.H.I.M. Hollink et al.
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Figure 1. CEBPA mutations and promoter hypermethylation in pedi-
atric AML cases. (A) Schematic representation of the CEBPA gene
and location of the identified mutations. (B) Representative picture
of methylation-specific (MSP) and unmethylation-specific PCR (USP)
products of the CEBPA promoter separated by 2% agarose gel elec-
trophoresis and visualized with ethidium bromide. Patient sample 6
shows a positive MSP product, indicating CEBPA promoter hyperme-
thylation. Ma: marker, numbers 1-11: patients’ samples, U:
unmethylated positive control, M: methylated positive control, C:
control bisulfite-untreated DNA, B: blank distilled H2O.
Ma 1 2 3 4 5 6 7 8 9 10 11 U M C B Ma
MSP
USP
aa 1 70 97 127 200 272 358
p42 p30
start start
single mutant
double mutant
TAD220,33 (n=7), with variation(s) that did not lead to
amino acid changes, or with a single amino acid change
(situated between the TAD1 and -2 domains) of unknown
significance (n=1) were considered to have wild-type
CEBPA.
Characteristics of CEBPA single- and double-mutant
cases of pediatric acute myeloid leukemia   
The clinical and cell-biological characteristics of the
study cohort are shown in Table 1. CEBPA double muta-
tions were not present in patients below the age of 3
years. However, the median age of patients with CEBPA
double-mutant AML (12.3 years) did not differ significant-
ly from that of patients with CEBPA single-mutant AML
(7.5 years) or with CEBPA wild-type AML (9.7 years)
(P=0.26). CEBPA double mutations occurred exclusively in
French-American-British (FAB) types M1 and M2, in con-
trast to single mutations, which were found in more
diverse FAB types (P=0.04). No statistical significant differ-
ences were detected between the three subgroups regard-
ing sex and white blood cell count at diagnosis.
Single and double CEBPAmutations did not occur in the
favorable cytogenetic subgroups [inv(16), t(8;21) and
t(15;17)] or in the MLL-rearranged subgroup. CEBPA dou-
ble mutations occurred mainly in cytogenetically normal
AML (57%), but five cases (36%) also carried an additional
cytogenetic aberration (Online Supplementary Table S2). In
one case (7%) cytogenetic analysis failed, but RT-PCR
and/or FISH excluded recurrent cytogenetic aberrations in
this case. CEBPA single mutations were present in three
cases with cytogenetic aberrations (50%), two cases
(33%) with a normal karyotype and in one case (17%)
cytogenetic analysis failed, but recurrent cytogenetic aber-
rations were excluded. Additional molecular aberrations
were equally frequent in the CEBPA single- and double-
mutants, and consisted of FLT3/ITD, RAS and WT1 muta-
tions, as described in Table 1. 
Identification of one case with gain of a single CEBPA
mutation at relapse
We screened 33 pairs of samples taken at initial diagno-
sis and relapse; these comprised three CEBPA-mutant (2
single and 1 double) and 30 CEBPA wild-type cases at ini-
tial diagnosis. All three CEBPA-mutated cases carried the
same mutations at relapse. Of the 30 CEBPA wild-type
cases at diagnosis, one case (3%) gained an N-terminal
frame shift mutation (c.226delG) in CEBPA at relapse, i.e.
10 months after diagnosis. The other (cyto)genetic aberra-
tions in this patient (45,X,-X and a WT1 mutation) were
present at both diagnosis and relapse.  
Frequency of germ-line origin of CEBPA mutations
Of 7 patients with CEBPA-mutated AML (4 single and 3
double mutants), remission material (bone marrow
mononuclear cells taken in full complete remission) was
available. In one case (14%) with CEBPA double-mutant
AML, the N-terminal frame shift mutation (c.69dupC) was
detected in the germ-line material; the second CEBPA
mutation in this patient, which was located in the bZIP
region (c.937_939dupAAG), was somatically acquired in
the leukemic cells. An FLT3/ITD was also somatically
acquired. This patient was diagnosed with AML at the age
of 6 years and died 14 months after diagnosis in continu-
ous complete remission because of bleeding. It was not
possible to test the CEBPAmutational status of the parents
as they could not be reached. Interestingly, in unsuper-
vised cluster analysis based on gene expression data
(Figure 3), this case (#4746) clustered together with the
other CEBPA double-mutant cases, indicating that, based
on gene expression profiles, the leukemia of this patient
was comparable with ‘sporadic’ CEBPA double-mutant
AML.
Prognostic impact of CEBPA single and double 
mutations in pediatric acute myeloid leukemia
Survival analysis was restricted to 185 patients with de
novo AML, including five with CEBPA single mutations
and ten with CEBPA double mutations (Online
Supplementary Tables S2 and S3). The median follow-up
period of the survivors was 4.4 years. All ten patients with
CEBPA double mutations reached complete remission
(100%), while complete remission was achieved in four
CEBPA aberrations in pediatric AML
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Table 1. Characteristics of the 252 pediatric AML patients included in this
study, divided by CEBPA mutation status.
All CEBPA single CEBPA double CEBPA P value
mutation mutation wild-type
Number 252 6 14 232
Age, median (years) 9.7 7.5 12.3 9.7 0.26*
<3 years, n (%) 49 1 (17%) - 48 (21%)
≥3 years, n (%) 203 5 (83%) 14 (100%) 184 (79%) 0.16#
Sex (% female) 45.2% 66.7% 42.9% 44.8% 0.56#
WBC (x109/L), median 42 20 60 41 0.69*
(range) (0-535) (8-535) (6-388) (0-483)
FAB classification, n(%) 0.001#
M0 12 (5%) 1 (17%) - 11 (5%)
M1 27 (11%) 2 (33%) 6 (43%) 19 (9%)
M2 55 (23%) 1 (17%) 8 (57%) 46 (21%)
M3 20 (8%) - - 20 (9%)
M4 60 (25%) 2 (33%) - 58 (26%)
M5 57 (24%) - - 57 (26%)
M6 3 (1%) - - 3 (1%)
M7 8 (3%) - - 8 (4%)
other 1 (0%) - 1 (0%)
Unknown 9 (4%) - - 9 (4%)
Karyotype, n(%) 0.049#
t(8;21) 27 (11%) - - 27 (12%)
inv(16) 26 (10%) - - 26 (11%)
t(15;17) 18 (7%) - - 18 (8%)
11q23 49 (19%) - - 49 (21%)
normal 55 (22%) 2 (33%) 8 (57%) 45 (19%)
other 60 (24%) 3 (50%) 5 (36%) 49 (21%)
unknown 17 (7%) 1 (17%) 1 (7%) 15 (7%)
FLT3/ITD, n(%) 52 (21%) 1 (17%) 3 (21%) 48 (21%) 0.97#
(n=252)
N- or K-RAS, n(%)  52 (21%) 1 (17%) 2 (14%) 49 (21%) 0.80#
(n=251)
c-KIT , n(%) 17 (7%) - - 17 (7%) 0.45#
(n=251)
MLL-PTD, n(%) 5 (2%) - - 5 (2%) 0.80#
(n=244)
NPM1, n(%) 18 (7%) - - 18 (8%) 0.43#
(n=247)
WT1, n(%)  27 (11%) 2(33%) 3 (21%) 22 (10%) 0.08#
(n=250)
*Kruskal-Wallis test; #Chi-square test; WBC: white blood cell count at diagnosis; FAB: French-
American British.
out of the five (80%) patients with CEBPA single muta-
tions, as one patient had resistant disease. The complete
remission rate for CEBPA wild-type patients (n=170) was
84%.
Patients with CEBPA double-mutant AML had a signif-
icantly better 5-year overall survival compared with those
with a single CEBPAmutation (5-year probability of over-
all survival 79±13% versus 25±22%; P=0.04), although the
5-year event-free survival was not significantly different
(5-year probability of event-free survival 58±16% versus
30%±24%; P=0.16) (Figure 2). In fact, the outcome of
patients with CEBPA double-mutations was comparable
to that of patients in the favorable-risk group with core-
binding factor AML [inv(16) or t(8;21)], who had a 5-year
probability of overall survival of 91±4%; P=0.51 and of
event-free survival of 61±9%; P=0.74. Furthermore,
patients with CEBPA double mutations showed a clear
trend to a more favorable outcome than patients with
wild-type CEBPA after excluding the core-binding factor-
AML cases (5-year probability of overall survival 47±5%;
P=0.07 and of event-free survival 33±4%; P=0.06). The
impact of additional molecular or cytogenetic aberrations
(e.g. FLT3/ITD) on the CEBPA single- and double-mutated
group could not be investigated due to small numbers.
Multivariate analysis, including age, white blood cell
count at diagnosis, favorable cytogenetics, NPM1 muta-
tions and FLT3/ITD, showed that the presence of a
CEBPA double mutation was an independent favorable
prognostic factor for overall survival (HR 0.23; P=0.04) as
well as event-free survival (HR 0.32; P=0.03) (Table 2).
CEBPA single mutations were not included in the multi-
variate analysis as a factor because of the small number of
cases.
Aberrant CEBPA promoter hypermethylation in pedi-
atric acute myeloid leukemia
Methylation-specific PCR could be performed in 237
cases and revealed hypermethylation of the CEBPA pro-
moter region in only three cases (1.3%) (Figure 1B). As
expected, CEBPA gene expression (determined with probe
set 204039_at and depicted in Figure 3) was down-regulat-
ed in these cases. The characteristics of these three
CEBPA-hypermethylated cases are shown in Table 3.
CEBPA promoter hypermethylation was also present in
the relapse material (n=2) from these patients, demon-
strating clonal stability of the hypermethylation pattern.
Unsupervised analysis reveals clustering of CEBPA
mutant and hypermethylated cases
Unsupervised cluster analysis of 237 children with de
novo AML showed distinct clusters (Figure 3A). Cases
with CEBPA mutations and promoter hypermethylation
predominantly clustered together, and are referred to as
the main CEBPA cluster. This cluster contained 15 cases in
total, including eight double-mutants and all three hyper-
methylated cases. Of interest, two cases of CEBPA single-
mutant AML were also present in this main CEBPA clus-
ter, despite the fact that these cases are expected to have
wild-type expression of C/EBPα p42, in contrast to
CEBPA double-mutant and hypermethylated cases.
Interestingly, extremely high TRIB2 expression (probe set
202478_at) was present in one of these CEBPA single-
mutant cases (#5041), which may explain the C/EBPα
p42-inhibition of its remaining allele, as TRIB2 directly
inactivates C/EBPα p42.34
Furthermore, the two remaining cases in the CEBPA
main cluster had low CEBPA gene expression, and clus-
tered closely with the three cases of CEBPA-hypermethy-
lated AML, despite the fact that we did not detect hyper-
methylation in these cases using methylation-specific
PCR (Figure 3B, Table 3). Of note, one of these cases also
had very high TRIB2 expression (#4728). So, taken togeth-
I.H.I.M. Hollink et al.
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Figure 2. Kaplan-Meier survival curves of overall survival and event-free survival according to CEBPA status in pediatric AML. Probability of
(A) overall survival and (B) event-free survival of four subgroups of patients with pediatric AML, i.e. CEBPA single-mutant AML, CEBPA dou-
ble-mutant AML, CEBPA wild-type non-core-binding factor (CBF) AML and CBF-AML.
Table 2. Results of multivariate analysis for overall survival (OS) and
event-free survival (EFS).
Outcome Variable Hazard 95% P
ratio confidence value
interval
Favorable karyotype 0.11 0.04-0.30 <0.001
CEBPA double mutation 0.23 0.06-0.96 0.04
OS NPM1mutation 0.43 0.17-1.09 0.08
WBC >50¥109/L 1.23 0.76-2.10 0.36
FLT3/ITD 1.28 0.70-2.34 0.42
Age >10 years 1.07 0.64-1.79 0.79
Favorable karyotype 0.27 0-15-0.47 <0.001
NPM1mutation 0.29 0.13-0.69 0.005
EFS CEBPA double mutation 0.32 0.12-0.89 0.03
FLT3/ITD 1.34 0.81-2.23 0.25
Age >10 years 1.18 0.78-1.78 0.46
WBC >50¥109/L 1.03 0.68-1.54 0.90
WBC: white blood cell count; OS: overall survival; EFS: event-free survival.
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er, five patients with silenced CEBPA were found among
237 cases of de novo pediatric AML (2.1%). Four of these
patients experienced a relapse, and only one patient was
in continuous complete remission after hematopoietic
stem cell transplantation (Table 3). 
Clearly, a common gene expression signature was
shared for all the cases in the CEBPA main cluster, which
was confirmed when comparing this cluster with all oth-
ers (Online Supplementary Figure S1, Online Supplementary
Table S4). 
T-cell characteristics of CEBPA-silenced cases
in pediatric acute myeloid leukemia
As CEBPA-silenced cases were reported to express T-cell
lineage genes and NOTCH1 mutations in adults, we next
investigated T-cell characteristics and screened for
NOTCH1 mutations in our five pediatric cases with
silenced CEBPA.15 Flow cytometry data revealed high CD7
expression in all five cases besides myeloid (CD33/CD13
and CD11b) and stem-cell markers (CD34 and CD117)
(Online Supplementary Table S5). One case expressed cCD3
weakly (#5033), but expression of other T-cell antigens
was not seen. However, high mRNA expression of CD3
(CD3Z: 210031_at, CD3G: 206804_at and CD3D:
213539_at) was seen in all cases (Online Supplementary
Table S5). High LCK expression, which is a well-known T-
lineage marker (probe set 204891_s_at),35 was also found
in all five cases. We did not detect NOTCH1 mutations in
the HD or PEST domain in our five CEBPA-silenced cases. 
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Figure 3. Unsupervised clustering of gene expression data revealed
clustering of cases with aberrant CEBPA predominantly in one clus-
ter in pediatric de novo AML. (A) Pair wise correlations between
gene expression profiles of 237 de novo pediatric AML samples,
calculated on the basis of 1608 probe sets (cutoff: 16-fold), are dis-
played in a correlation plot. Colors of boxes represent the
Pearson’s correlation coefficient with a color gradient ranging from
deep blue for a negative correlation, to vivid red for a positive cor-
relation. Distinct clusters of samples, which can be recognized by
the red blocks showing strong correlation along the diagonal, are
observed. The first column to the right of the plot indicates the
major cytogenetic subgroup the samples belong to [dark blue:
inv(16), pale red: t(8;21), bright blue t(15;17), yellow: t(7;12), light
blue: 11q23, dark gray: normal cytogenetics, light gray: other cyto-
genetic aberrations and white: failure]. Clustering of these cytoge-
netic subgroups is seen. The second, third and fourth columns rep-
resent presence (blue) or absence (yellow) of a CEBPA mutation,
CEBPA double mutation and CEBPA promoter methylation, respec-
tively. The majority of CEBPA mutant cases aggregated together
with all CEBPA hypermethylated cases in one main cluster. (B) An
enlarged view of the correlation plot focusing on the CEBPA main
cluster is shown. The order of the patients’ samples in this cluster
from top to bottom is as follows: #4728, #5033, #3496, #3451,
#4736, #3439, #5041, #5061, #4746, #5063, #5047, #4396,
#4445, #4747, #5013.  Additionally, four histograms show the
expression of CEBPA (204039_at), CD7 (214551_s_at), CD3D
(213539_at) and TRIB2 (202478_at). Within the CEBPA main clus-
ter, two sub-clusters based on expression of CEBPA can be identi-
fied and are separated by a gray line, i.e. CEBPA low or absent
expression (n=5), including the three CEBPA promoter methylated
cases, and CEBPA high expression with the CEBPA mutant cases
(n=10). The five silenced CEBPA cases are further characterized by
high CD3 and CD7 expression. Silenced case #4728 and single-
mutated case #5041 show high TRIB2 expression, which has been
shown to inhibit C/EBPα p42.
Table 3. Characteristics of the five CEBPA-silenced AML cases, including three cases with CEBPA promoter hypermethylation.
ID MSP* Age Sex WBC FAB Karyotype Molecular Treatment Follow-up
(years) (x109/L) aberration protocol
#3451 + 6,3 male 196 M0 46,XY,del(17)(p12p13) or add(17)(p11)[2] WT1, N-RAS DCOG97 relapse after 11.7 months
#3496 + 11,3 female NA M5 NA WT1, K-RAS DCOG97 relapse after 8.2 months
#5033 + 10,3 female NA M0 46,XX,t(3;4)(q11-12;p15-16)[6]/ none LAME CCR for 8.5 years (stem
47,XX,t(3;4)(q11-12;p15-16),+mar[12]/ cell transplant 8 
46,XX[2] months after diagnosis)
#4728 - 9,7 male 2.4 M0 47,XY,inv(12)(p1?3,q1?3),+19[6]/46,XY[14] none DCOG97 relapse after 38.4 months
#4736 - 8,5 female 2.9 M4 46,XX,del(7)?(p13;p21)[1], idem + t(3;7)? none DCOG97 relapse after 7.3 months
(p25;p15)[11], idem + del(11)?(p11p14)[13]
*MSP: methylation-specific PCR for CEBPA promoter hypermethylation: + positive, - negative; NA: not available; WBC: white blood cell count; CCR: continuos complete remission.
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Prediction of CEBPA double-mutant and -silenced cases
using adult acute myeloid leukemia gene signatures
We utilized previously established gene prediction sig-
natures in adult AML, based on 21- and 9-probe sets for
CEBPA double-mutant and CEBPA-silenced cases, respec-
tively.15,27 Of the 12 CEBPA double-mutant cases, ten were
correctly predicted using the 21-probe set-containing sig-
nature, one was predicted as being a single mutant, and
one as a silenced case (sensitivity 83%, specificity 99%)
(Online Supplementary Table S6A). Visualizing these results,
it can be seen that the double-mutant cases form a main
cluster apart from the wild-type cases (Online
Supplementary Figure S2A,B). However, three CEBPA sin-
gle-mutant cases (1 predicted as a double mutant), with
the single mutation located in the bZIP region, also clus-
tered with the CEBPA double-mutant cases. 
The 9-probe set-signature for CEBPA-silenced cases pre-
dicted three of our five silenced cases, but also one CEBPA
wild-type was false positively recognized (Online
Supplementary Table S6B, Online Supplementary Figure
S2C,D). This resulted in a low sensitivity (60%) of these
probe sets for the prediction of CEBPA-silenced cases in
our pediatric series.
Discussion
In this study we investigated CEBPA aberrations in pedi-
atric AML to determine their frequency and prognostic
impact, and also to gain further insight into the biology of
pediatric AML with CEBPA aberrations. We detected
CEBPA mutations in 7.9% of pediatric AML cases, which
is comparable to the reported frequency in adult AML (5-
14%),9,21-24 and the two available pediatric series from
Taiwan (6%) and North-America (4.5%).25,26 Seventy per-
cent of CEBPA-mutated cases carried a double mutation,
which is in agreement with previous studies reporting that
the majority of CEBPA-mutated cases carried double
mutations, typically affecting both alleles.20,21
Recently, two reports on adult series postulated that
CEBPA single- and double-mutant AML are different enti-
ties, as a favorable outcome was associated uniquely with
CEBPA double mutants.27,28 Moreover, patients with double
mutations were characterized by a specific gene expression
signature, in contrast to those with CEBPA single muta-
tions. This is further sustained by recently published data
from mouse models that showed an efficient synergistic
effect of the two different CEBPA mutations on leukemic
transformation.36-38 Single CEBPA mutations are, however,
believed to predispose the pre-leukemic initiating cell to
subsequent acquirement of secondary (epi)genetic muta-
tions necessary before the development of full-blown
AML.37-38 Despite small numbers, we observed differences,
both in presenting characteristics as well as in prognosis,
between CEBPA single- and double-mutant AML. With
regards to presenting characteristics, CEBPA double-mutant
AML did not occur in very young patients, was restricted to
FAB M1/M2 subtypes, and had the strongest association
with cytogenetically normal AML. However, the frequency
of additional molecular mutations was not higher in CEBPA
single-mutant cases than in CEBPA double-mutant cases. 
With regards to prognosis, only patients with CEBPA
double mutations were associated with a favorable out-
come, with a 5-year overall survival of 79%. Those with
single mutations had a relatively poor outcome in our
series (5-year probability of overall survival of 25%). In
fact, the outcome of the CEBPA double-mutant cases was
comparable to that of the subgroup with the favorable
core-binding factor-AML. This is in agreement with the
results of the pediatric Children’s Oncology Group
study,25 which showed an overall survival of approxi-
mately 80% at 5 years for patients with CEBPA double-
mutant AML. Multivariate analysis confirmed the inde-
pendent prognostic significance of CEBPA double muta-
tions, which points to its potential as a marker for further
refinement of risk-group stratification in pediatric AML,
when validated in prospective series. 
The mechanism of the relative drug sensitivity of the
CEBPA double-mutated cases remains to be elucidated.
The outcome of cases with a single mutation in the series
reported by the Children’s Oncology Group (5-year pre-
dicted overall survival of 85%) was similar to that of the
cases with double mutations. Despite the fact that the
numbers of single-mutant cases in both series were small,
we hypothesize that the difference in outcome between
our studies may be based on the underlying biology of
the type of the single mutation (i.e. a mutation at the N-
terminus, bZIP region or other location) as different
leukemogenic capacities have been associated with the
different types of mutation,37 or by different cooperating
genetic events. Further studies of the single-mutant group
in pediatric and adult AML are clearly warranted to deter-
mine the impact of the different mutation types and
cooperating genetic aberrations. 
Germ-line CEBPA mutations have been discovered in
familial AML, in which the N-terminal mutation is present
in the germ-line, and frequently a second CEBPA bZIP
mutation is somatically acquired as a second hit to devel-
op AML.39,40 The frequency of germ-line mutations in adult
AML with CEBPA mutations was estimated at 11% (2
cases out of 18).41 Here we found a similar frequency: one
out of seven cases of pediatric CEBPA-mutated AML had
a germ-line mutation. In our pediatric case we also found
an N-terminal mutation in the germ-line, and a somatical-
ly acquired bZIP mutation. The occurrence of AML in
both children and adults with germ-line CEBPAmutations
illustrates a variable latency time. 
Promoter hypermethylation of CEBPA was present at a
low frequency in our pediatric series. These hypermethy-
lated cases showed CEBPA-silencing and, utilizing unsu-
pervised clustering of gene expression data, clustered
together with the double-mutant cases. Two other cases
with CEBPA-silencing without promoter hypermethyla-
tion were detected; these two cases clustered together
with the hypermethylated cases. The mechanism of gene
silencing in these two cases still has to be elucidated, but
could be hypermethylation in other regions of the pro-
moter,42 silencing by other epigenetic processes or by bind-
ing of microRNA. All five CEBPA-silenced cases had T-
lymphoid characteristics beside their myeloid and stem
cell markers. However, no NOTCH1 mutations were
detected, which may be due to the small number of cases
as NOTCH1mutations were present in only 50% of adult
cases with silenced CEBPA.15 In contrast to the favorable
outcome of patients with CEBPA double mutations, four
out of the five CEBPA-silenced cases experienced a
relapse. Interestingly, the patient who did not relapse had
received a stem cell transplant. Cases with silenced CEBPA
due to hypermethylation might potentially benefit from
the use of demethylating agents.
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Clustering of CEBPA-silenced and double-mutant cases
points towards a common feature of C/EBPα inactivation
in these leukemias. Cases in this CEBPAmain cluster clear-
ly shared a specific gene expression profile. However, the
main cluster could also be divided into two sub-clusters,
separating the double-mutant and silenced cases, which
might also underlie biological factors influencing drug
resistance and thereby the difference in prognosis between
the two subgroups. Differences in methylation profiles
have already been shown between these two subgroups.43
Interestingly, two CEBPA single-mutant cases, which are
expected to have full-length C/EBPα p42 expression of the
unaffected allele, also aggregated in this cluster. In one of
these cases, high TRIB2 expression was detected, which is
known to directly inactivate the C/EBPα p42 isoform.34
Complete C/EBPα p42 inactivation of the wild-type allele
is hereby established and clustering with cases of AML
without functional C/EBPα p42 can be explained. The
mechanism of the expected C/EBPα p42 inactivation in the
other single-mutant case remains to be elucidated. 
We tried to predict CEBPA double-mutant and silenced
cases in our pediatric series based on a prediction signa-
ture derived from adult studies. A high sensitivity and
specificity was reached for CEBPA double-mutants,
although one single-mutant case was also falsely predict-
ed, and two single-mutant cases clustered with the dou-
ble-mutant cases. These three cases did, however, carry a
mutation in the bZIP region, which was previously shown
to have a tendency towards a CEBPA double-mutant gene
expression profile.27 Prediction of the CEBPA-silenced
cases was difficult due to a low sensitivity.
In conclusion, we showed the independent favorable
outcome of patients with CEBPA double-mutant AML in a
large series of pediatric AML. Hence, CEBPA double muta-
tions may improve risk-group stratification in pediatric
AML, if these data are validated in prospective series. For
the first time, CEBPA-silencing is suggested to confer a
poor outcome in pediatric AML, warranting further inves-
tigation of this CEBPA aberration. Furthermore, clustering
of gene expression profiles provided insight into the bio-
logical similarities and diversities of CEBPA aberrations in
pediatric AML.
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